| Descriptive Information Fields | |
|---|---|
| Brief Title † | Endothelial Progenitor Cells and Risk Factors for Coronary Artery Disease |
| Official Title † | Endothelial Progenitor Cells and Risk Factors for Coronary Artery Disease |
| Brief Summary | This study will measure and compare the levels of endothelial progenitor cells (EPCs) in the blood of people with and without risk factors for atherosclerosis (hardening of the arteries) to see if there is a relationship between these cells and cardiovascular risk factors such as smoking, high cholesterol level and high blood pressure. Healthy male volunteers between the ages of 21 and 55 years with and without heart disease risk factors may be eligible for this study. Candidates must have no evidence of coronary or peripheral vascular disease, proliferative retinopathy, or other chronic disease and no history of cancer, migraine-type headache, cluster headache, raised intraocular pressure, raised intracranial pressure, hyperthyroidism. Participants will undergo the following procedures at the NIH Clinical Center:
|
| Detailed Description | Evidence suggests that risk factors for atherosclerosis contribute to atherogenesis by causing endothelial injury. However, little is known about determinants of endothelial cell repair and regeneration. We propose that mobilization of endothelial progenitor cells (EPCs) constitutes one mechanism for ongoing endothelial repair. EPCs are a bone marrow derived cell population that can be isolated from peripheral blood. Among human peripheral mononuclear cells, EPCs are relatively abundant with an estimated frequency of 1 in 500 to 1 in 1000 cells. Evidence suggests that EPCs can participate in angiogenesis under pathophysiological circumstances. Under normal conditions, however, adult organisms undergo little if any active angiogenesis. One explanation for this set of observations is that high circulating levels of EPCs may exist to allow these cells to participate in functions beyond angiogenesis. We hypothesize that one such function is in the repair of ongoing endothelial injury. To test this hypothesis, we will measure peripheral blood EPC activity by ascertaining the number of EPC colony forming units from peripheral blood sampling. We intend to correlate this biological determinant with the degree of endothelial dysfunction assessed by flow-mediated brachial artery reactivity, and an atherosclerotic risk stratification method developed by the Framingham study. We hypothesize that a correlation will exist between the atherosclerotic risk profile, endothelial function and EPC activity and that the EPC activity will therefore become a novel surrogate biological marker for cumulative cardiovascular risk. |
| Study Phase | |
| Study Type † | Observational |
| Study Design † | |
| Primary Outcome Measure † | |
| Secondary Outcome Measure † | |
| Condition † | Coronary Arteriosclerosis |
| Intervention † | |
| MEDLINE PMIDs | 9657732, 9020076, 8479518 |
| Links | |
| Recruitment Information Fields | |
| Recruitment Status † | Completed |
| Enrollment † | 120 |
| Start Date † | March 2001 |
| Completion Date | March 2003 |
| Eligibility Criteria † | INCLUSION CRITERIA: Men: aged 21 and above with or without cardiovascular risk factors Women - post menopausal (based on clinical history) with and without cardiovascular risk factors EXCLUSION CRITERIA: Pre-menopausal women History of cancer Evidence of proliferative retinopathy History of migraine-type headache History of cluster headache History of raised intraocular pressure History of raised intracranial pressure Hypersensitivity to organic nitrates History of hyperthyroidism Any intercurrent illness Any other chronic disease not including cardiovascular risk factors. No current medications including vitamins for at least 1 week. |
| Gender | Both |
| Ages | |
| Accepts Healthy Volunteers | No |
| Contacts †† | |
| Location Countries † | United States |
| Administrative Information Fields | |
| NCT ID † | NCT00013975 |
| Organization ID | 010119 |
| Secondary IDs †† | 01-H-0119 |
| Study Sponsor † | National Heart, Lung, and Blood Institute (NHLBI) |
| Collaborators †† | |
| Investigators † | |
| Information Provided By | National Institutes of Health Clinical Center (CC) |
| Verification Date | March 2003 |
| First Received Date † | April 4, 2001 |
| Last Updated Date | March 3, 2008 |